期刊文献+

二甲双胍对于不同体质糖尿病患者治疗效果及临床价值研究

下载PDF
导出
摘要 目的探究二甲双胍对于不同体质糖尿病患者治疗效果及临床价值。方法本次研究对象从近年来我院就诊的2型糖尿病中选取80例,根据中医体质量表分为痰湿质患者(观察组)与阴虚质患者(对照组),两组患者都采用二甲双胍治疗,探究两组患者治疗后的相关指标、不良反应发生率和治疗效果。结果观察组患者治疗后的相关指标优于对照组(P<0.05);观察组患者的不良反应发生率低于对照组(P<0.05);观察组患者治疗效果优于对照组(P<0.05)。结论二甲双胍治疗痰湿质糖尿病患者的效果相较于阴虚质糖尿病患者较优,且患者出现肠胃不良反应的情况更少。
作者 彭露萍
出处 《实用妇科内分泌电子杂志》 2020年第10期154-154,156,共2页 Electronic Journal of Practical Gynecological Endocrinology
  • 相关文献

参考文献3

二级参考文献24

  • 1Whiting DR,Guariguata L,Weil C,et al.IDF diabetes ailas:global estimates of the prevalence of diabetes for 2011 and 2030[J].Diabetes Res Clin Pract,2011,94:311-321. 被引量:1
  • 2Dharmalingam M,Sriram U,Baruah MP.Liraglutide:a review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus[J].Indian J Endocrinol Metab,2011,15:9-17. 被引量:1
  • 3Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the american diabetes association(ADA)and the European Association for the Study of Diabetes(EASD)[J].Diabetologia,2012,55:1577-1596. 被引量:1
  • 4Marre M,Shaw J,Brandle M,et al.Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes(LEAD-1 SU)[J].Diabetic Medicine,2009,26(3):268-278. 被引量:1
  • 5Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide,glimepiride and placebo,all in combi-nation with metformin in type 2 diabetes the LEAD(liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,32(1):84-90. 被引量:1
  • 6Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomized,52 week,phaseⅢ,double blind,parallel treatment trial[J].Lancet,2008,373(9662):473-481. 被引量:1
  • 7Zinman B,Gerich J,Bush JB,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combi-nation with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met+TZD)[J].Diabetes Care,2009,32(7):1224-1230. 被引量:1
  • 8Russell-Jones D,Vaag A,Schmitz O,et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes millitus(LEAD-5 met+SU):a randomised conerolled trial[J].Diabetologia,2009,52(10):2046-2055. 被引量:1
  • 9Bush JB,Rosenstock J,Sesti G,et al.Lirglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomized,parallel group,multinational,open label trial(LEAD-6)[J].Lancet,2009,374(9683):39-47. 被引量:1
  • 10Baggio LL,Drucker DJ.Biology of incretins:GLP-1 and GIP[J].Gastroenterology,2007,132:2131-2157. 被引量:1

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部